We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMO
51
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.77M 0.29%
443,286
+266,021
+150% +$3.83M
RMTI icon
52
PUT
Rockwell Medical
RMTI
$27.6M
$6.48M 0.28%
49
-2
-4% -$2.41K
SLXP
53
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$6.09M 0.26%
49,403
+47,233
+2,177% +$5.22M
RPRX
54
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
$5.97M 0.26%
3,450
+79
+2% +$1.29K
ELV icon
55
CALL
Elevance Health
ELV
$83.7B
$5.94M 0.25%
+552
New +$56.9K
AMGN icon
56
Amgen
AMGN
$212B
$5.88M 0.25%
49,703
+7,392
+17% +$856K
ITMN
57
PUT
DELISTED
INTERMUNE INC
ITMN
$5.82M 0.25%
1,318
-3,363
-72% -$124K
ITMN
58
CALL
DELISTED
INTERMUNE INC
ITMN
$5.45M 0.23%
1,235
-5,389
-81% -$198K
GWPH
59
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.2M 0.22%
+485
New +$33.7K
TSLA icon
60
Tesla
TSLA
$1.21T
$5.17M 0.22%
+323,355
New +$4.51M
SRPT icon
61
PUT
Sarepta Therapeutics
SRPT
$1.63B
$5.04M 0.22%
1,693
-2,367
-58% -$74.8K
SRPT icon
62
CALL
Sarepta Therapeutics
SRPT
$1.63B
$4.88M 0.21%
1,638
+1,287
+367% +$40.7K
QPAC
63
DELISTED
QUINPARIO ACQUISITION CORP COM STK
QPAC
$4.84M 0.21%
+461,756
New +$4.73M
THMO
64
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
$4.61M 0.2%
369
+310
+525% +$4.49M
AKTX
65
Akari Therapeutics
AKTX
$14.8M
$4.51M 0.19%
102
+18
+21% +$824K
NPSP
66
PUT
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$4.35M 0.19%
+1,315
New +$38K
PSTV icon
67
Plus Therapeutics
PSTV
$25.9M
$4.29M 0.18%
+1
New +$6.73M
ARWR icon
68
PUT
Arrowhead Research
ARWR
$12.1B
$4.28M 0.18%
2,989
+511
+21% +$6.7K
BLRX
69
BioLineRX
BLRX
$12.2M
$4.2M 0.18%
3,369
+198
+6% +$248K
AZN icon
70
AstraZeneca
AZN
$267B
$4.18M 0.18%
+56,275
New +$4.07M
TSRO
71
CALL
DELISTED
TESARO, Inc.
TSRO
$3.98M 0.17%
1,281
+1,141
+815% +$30.4K
SRPT icon
72
Sarepta Therapeutics
SRPT
$1.63B
$3.78M 0.16%
126,772
-225,328
-64% -$7.12M
UNH icon
73
CALL
UnitedHealth
UNH
$389B
$3.68M 0.16%
+450
New +$35.4K
DRNA
74
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.45M 0.15%
152,994
+101,484
+197% +$1.84M
UTHR icon
75
CALL
United Therapeutics
UTHR
$26.1B
$3.44M 0.15%
389
-121
-24% -$11.6K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.